Get the Stockscreener App
14.02
4.08%
0.55
Anika Therapeutics Inc stock is traded at $14.02, with a volume of 95,492.
It is up +4.08% in the last 24 hours and down -12.97% over the past month.
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of its revenue from the United States.
See More
Previous Close:
$13.47
Open:
$13.78
24h Volume:
95,492
Relative Volume:
1.36
Market Cap:
$196.90M
Revenue:
$166.88M
Net Income/Loss:
$-74.18M
P/E Ratio:
-2.7653
EPS:
-5.07
Net Cash Flow:
$1.14M
1W Performance:
+3.09%
1M Performance:
-12.97%
6M Performance:
-44.25%
1Y Performance:
-45.43%
1-Day Range:
$13.29
$14.73
1-Week Range:
$13.14
$14.73
52-Week Range:
$12.83
$29.11
Anika Therapeutics Inc Stock (ANIK) Company Profile
Name
Anika Therapeutics Inc
Sector
Phone
(781) 457-9000
Address
32 WIGGINS AVENUE, BEDFORD, MA
Compare ANIK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANIK
Anika Therapeutics Inc
|
14.02 | 196.90M | 166.88M | -74.18M | 1.14M | -5.07 |
|
ZTS
Zoetis Inc
|
148.67 | 67.28B | 9.26B | 2.49B | 2.30B | 5.47 |
|
HLN
Haleon Plc Adr
|
10.22 | 45.62B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.71 | 45.01B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
13.65 | 15.60B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
284.73 | 12.77B | 2.76B | 1.11B | 898.10M | 22.77 |
Anika Therapeutics Inc Stock (ANIK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-25 | Initiated | B. Riley Securities | Buy |
| Nov-01-24 | Reiterated | Barrington Research | Outperform |
| Aug-14-23 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Mar-07-23 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-09-22 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Oct-14-22 | Resumed | Stephens | Equal-Weight |
| Mar-09-22 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-09-22 | Downgrade | Stephens | Overweight → Equal-Weight |
| Nov-16-21 | Initiated | Stephens | Overweight |
| Jul-16-21 | Initiated | UBS | Neutral |
| Dec-16-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-08-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-21-20 | Upgrade | Sidoti | Neutral → Buy |
| Jan-10-20 | Upgrade | First Analysis Sec | Outperform → Strong Buy |
| Nov-05-19 | Initiated | BWS Financial | Sell |
| Sep-24-19 | Reiterated | Barrington Research | Outperform |
| Sep-23-19 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| Jul-25-19 | Upgrade | First Analysis Sec | Neutral → Strong Buy |
| Feb-22-19 | Downgrade | First Analysis Sec | Outperform → Neutral |
| Feb-22-19 | Downgrade | Sidoti | Buy → Neutral |
| Jul-27-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jun-20-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jun-20-18 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| May-04-18 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Feb-23-18 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Jan-24-18 | Upgrade | First Analysis Sec | Equal-Weight → Overweight |
| Oct-27-17 | Reiterated | Barrington Research | Outperform |
| May-09-16 | Upgrade | Singular Research | BUY - Long-Term → Buy |
| Apr-27-16 | Downgrade | Northland Capital | Outperform → Market Perform |
| Feb-26-16 | Reiterated | Barrington Research | Outperform |
View All
Anika Therapeutics Inc Stock (ANIK) Latest News
Anika Therapeutics (NASDAQ:ANIK) Upgraded at B. Riley - Defense World
B. Riley Initiates Coverage on Anika Therapeutics (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Q4 2024 Earnings Call Transcript - MSN
B. Riley Initiates Anika Therapeutics at Buy With $21 Price Target - marketscreener.com
Anika Therapeutics (ANIK) Receives 'Buy' Rating with $21 Target from B. Riley Analyst | ANIK Stock News - GuruFocus
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Purchased by Wellington Management Group LLP - Defense World
Viscosupplementation Market Is Booming Worldwide 2025-2032 | - openPR.com
Arrowstreet Capital Limited Partnership Has $979,000 Stock Holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK) - Defense World
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Bought by American Century Companies Inc. - Defense World
Anika Therapeutics announces COO departure, streamlines management By Investing.com - Investing.com Canada
Anika Therapeutics announces COO departure, streamlines management - Investing.com
Anika Therapeutics Announces COO Departure and Role Elimination - TipRanks
Viscosupplementation Market Outlook: Growth Drivers - openPR.com
Anika Therapeutics stock hits 52-week low at $13.7 - Investing.com Australia
Anika Therapeutics stock hits 52-week low at $13.7 By Investing.com - Investing.com South Africa
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - MarketScreener
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Anika Grants 3,800 Share Options to New Hire: Key Details Revealed - Stock Titan
Anika Therapeutics, Inc. (NASDAQ:ANIK) Position Trimmed by HighTower Advisors LLC - Defense World
Are Options Traders Betting On A Big Move In Anika Therapeutics (ANIK) Stock? - Barchart.com
Are Options Traders Betting on a Big Move in Anika Therapeutics (ANIK) Stock? - TradingView
Viscosupplementation Market Is Booming Worldwide | Anika - openPR.com
Europe Viscosupplementation Market Projected To Witness - openPR.com
Anika Therapeutics stock hits 52-week low at $14.9 By Investing.com - Investing.com South Africa
Anika Therapeutics stock hits 52-week low at $14.9 - Investing.com India
How the (ANIK) price action is used to our Advantage - news.stocktradersdaily.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Stock Position Reduced by Charles Schwab Investment Management Inc. - Defense World
Hammertoe Solution Market Size, Trends 2031 By Key Players- - openPR.com
Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Acquired by Bank of New York Mellon Corp - Defense World
Europe Viscosupplementation Market Set to Witness Significant - openPR.com
Reviewing Anika Therapeutics (NASDAQ:ANIK) and InspireMD (NYSE:NSPR) - Defense World
Anika Therapeutics Faces Financial Strain Amid Geopolitical Tensions and Supply Chain Disruptions - TipRanks
Anika Therapeutics, Inc. SEC 10-K Report - TradingView
Viscosupplementation Market Is Booming Worldwide | Anika Therapeutics Inc., Seikagaku Corporation - openPR.com
Q1 Earnings Forecast for ANIK Issued By Barrington Research - Defense World
Anika Therapeutics (NASDAQ:ANIK) Stock Rating Upgraded by StockNews.com - Defense World
Barrington Research Lowers Anika Therapeutics (NASDAQ:ANIK) Price Target to $20.00 - Defense World
Anika Therapeutics (NASDAQ:ANIK investor three-year losses grow to 45% as the stock sheds US$26m this past week - Simply Wall St
Anika Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo
Anika Therapeutics stock hits 52-week low at $15.34 By Investing.com - Investing.com Australia
Anika Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks
Anika Therapeutics stock hits 52-week low at $15.34 - Investing.com
Earnings call transcript: Anika Therapeutics Q4 2024 beats EPS forecast, stock dips - Investing.com Australia
Anika Therapeutics Inc (ANIK) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges - Yahoo Finance
Anika Therapeutics Inc Stock (ANIK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.74%
0.80%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):